GlassScriptPhysician profile
Dan T Brody
NPI 1376606624
$9,290.52
in general payments reported to CMS, 2019-2025
29 companies · $2,636 in 2025
The $2,636 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,290 · 2021: $1,234 · 2022: $1,206 · 2023: $1,386 · 2024: $1,539 · 2025: $2,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,560.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,723.71 | 2020-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $1,299.84 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,074.33 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $624.17 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $414.32 | 2020-2025 | Dupixent |
| Genentech USA, INC. | $411.74 | 2020-2025 | Xolair |
| Pfizer INC. | $393.36 | 2020-2025 | |
| Optinose US, INC. | $355.14 | 2020-2025 | |
| Amgen INC. | $330.82 | 2022-2025 | Tezspire |
| Kaleo, INC. | $268.85 | 2020-2023 | Auvi-Q |
| Grifols USA, LLC | $220.12 | 2022-2025 | Prolastin-C Liquid, Xembify, Gamunex-C |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.15 | 2020-2024 | Jardiance |
| Ars Pharmaceuticals Operations, INC. | $171.52 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $133.73 | 2023-2025 | Ryaltris |
| Incyte Corporation | $115.23 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $89.91 | 2022 | |
| Leo Pharma INC. | $80.39 | 2022-2023 | Adbry |
| Takeda Pharmaceuticals U.S.A., INC. | $51.25 | 2023-2024 | Cuvitru, Takhzyro |
| Aimmune Therapeutics, INC. | $47.69 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $45.78 | 2021 | |
| Blueprint Medicines Corporation | $42.16 | 2025 | Ayvakit |
| Covis Pharma Gmbh | $37.28 | 2020 | |
| Biocryst US Sales Co., LLC | $28.24 | 2025 | Orladeyo |
| Alk-Abello, INC | $23.77 | 2020 | |
| Sunovion Pharmaceuticals INC. | $21.97 | 2020 | |
| Uswm, LLC | $21.00 | 2021 | |
| Galderma Laboratories, L.P. | $21.00 | 2025 | Nemluvio |
| Seqirus USA INC | $19.59 | 2025 | Fluad, Flucelvax |
| Phadia US INC. | $17.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Brody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.